XML 69 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Segments of Business and Geographic Areas (Tables)
 9 Months Ended
Sep. 29, 2019
Segment Reporting [Abstract]  
Sales By Segment Of Business

SALES BY SEGMENT OF BUSINESS
 
 
Fiscal Third Quarter Ended
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 29,
2019
 
September 30,
2018
 
Percent
Change
 
September 29,
2019
 
September 30,
2018
 
Percent Change
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
$
91

 
120

 
(24.1
)%
 
$
277

 
306

 
(9.5
)%
     International
 
326

 
352

 
(7.3
)
 
977

 
1,079

 
(9.5
)
     Worldwide
 
417

 
472

 
(11.6
)
 
1,254

 
1,385

 
(9.5
)
Beauty
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
559

 
543

 
2.9

 
1,810

 
1,791

 
1.1

     International
 
592

 
535

 
10.8

 
1,633

 
1,480

 
10.4

     Worldwide
 
1,151

 
1,078

 
6.8

 
3,443

 
3,271

 
5.3

Oral Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
156

 
158

 
(1.1
)
 
462

 
472

 
(2.1
)
     International
 
223

 
226

 
(1.6
)
 
673

 
684

 
(1.7
)
     Worldwide
 
379

 
384

 
(1.4
)
 
1,135

 
1,156

 
(1.8
)
OTC
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
477

 
440

 
8.4

 
1,468

 
1,359

 
8.0

     International
 
621

 
608

 
2.2

 
1,781

 
1,827

 
(2.5
)
     Worldwide
 
1,098

 
1,048

 
4.8

 
3,249

 
3,186

 
2.0

Women's Health
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3

 
3

 
(4.0
)
 
9

 
10

 
(3.8
)
     International
 
252

 
266

 
(5.4
)
 
724

 
782

 
(7.5
)
     Worldwide
 
255

 
269

 
(5.3
)
 
733

 
792

 
(7.4
)
Wound Care/Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
109

 
106

 
1.9

 
343

 
344

 
(0.4
)
     International
 
59

 
58

 
3.3

 
173

 
183

 
(5.0
)
     Worldwide
 
168

 
164

 
2.4

 
516

 
527

 
(2.0
)
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,394

 
1,370

 
1.7

 
4,369

 
4,282

 
2.0

     International
 
2,075

 
2,045

 
1.4

 
5,962

 
6,035

 
(1.2
)
     Worldwide
 
3,469

 
3,415

 
1.6

 
10,331

 
10,317

 
0.1

 
 
 
 
 
 
 
 
 
 
 
 
 

PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,582

 
2,400

 
7.6

 
7,124

 
6,717

 
6.1

     International
 
1,129

 
998

 
13.2

 
3,304

 
3,061

 
8.0

     Worldwide
 
3,711

 
3,398

 
9.3

 
10,428

 
9,778

 
6.7

     REMICADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
749

 
987

 
(24.1
)
 
2,324

 
2,821

 
(17.6
)
     U.S. Exports
 
88

 
100

 
(12.0
)
 
226

 
346

 
(34.7
)
     International
 
299

 
292

 
2.5

 
795

 
921

 
(13.7
)
     Worldwide
 
1,136

 
1,379

 
(17.6
)
 
3,345

 
4,088

 
(18.2
)
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
313

 
281

 
11.6

 
857

 
779

 
10.0

     International
 
273

 
255

 
7.3

 
816

 
823

 
(0.8
)
     Worldwide
 
586

 
536

 
9.6

 
1,673

 
1,602

 
4.5

     STELARA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,212

 
889

 
36.3

 
3,152

 
2,460

 
28.1

     International
 
487

 
421

 
15.7

 
1,509

 
1,252

 
20.5

     Worldwide
 
1,698

 
1,310

 
29.6

 
4,661

 
3,712

 
25.6

     TREMFYA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
221

 
143

 
54.3
 
565

 
311

 
81.7%
     International
 
69

 
28

 
*
 
177

 
58

 
*
     Worldwide
 
290

 
171

 
69.0
 
742

 
369

 
*
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—
 
—

 
—

 
—
     International
 
2

 
2

 
(4.4)
 
8

 
7

 
13.7
     Worldwide
 
2

 
2

 
(4.4)
 
8

 
7

 
13.7
 
 
 
 
 
 
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
418

 
345

 
21.2

 
1,162

 
1,006

 
15.5

     International
 
421

 
478

 
(12.0
)
 
1,385

 
1,496

 
(7.4
)
     Worldwide
 
839

 
823

 
1.9

 
2,547

 
2,502

 
1.8

     EDURANT® / rilpivirine
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
12

 
13

 
(7.3
)
 
36

 
42

 
(14.3
)
     International
 
206

 
189

 
9.0

 
603

 
581

 
3.8

     Worldwide
 
218

 
202

 
7.9

 
639

 
623

 
2.6

     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
373

 
297

 
25.4

 
1,032

 
847

 
21.8

     International
 
135

 
193

 
(29.8
)
 
534

 
613

 
(12.8
)
     Worldwide
 
508

 
490

 
3.7

 
1,566

 
1,460

 
7.3

     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
33

 
35

 
(4.3
)
 
94

 
117

 
(19.6
)
     International
 
80

 
96

 
(17.4
)
 
248

 
302

 
(18.2
)
     Worldwide
 
113

 
131

 
(13.9
)
 
342

 
419

 
(18.6
)
 
 
 
 
 
 
 
 
 
 
 
 
 

Neuroscience
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
785

 
651

 
20.7

 
2,172

 
1,914

 
13.5

     International
 
810

 
839

 
(3.5
)
 
2,590

 
2,663

 
(2.7
)
     Worldwide
 
1,595

 
1,490

 
7.1

 
4,762

 
4,577

 
4.0

     CONCERTA® / methylphenidate
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
84

 
57

 
48.2

 
196

 
191

 
2.9

     International
 
109

 
100

 
9.4

 
348

 
322

 
8.0

     Worldwide
 
193

 
157

 
23.5

 
544

 
513

 
6.1

     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
554

 
468

 
18.3

 
1,543

 
1,306

 
18.1

     International
 
297

 
281

 
5.9

 
916

 
859

 
6.7

     Worldwide
 
851

 
749

 
13.7

 
2,459

 
2,165

 
13.6

     RISPERDAL CONSTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
79

 
76

 
4.9

 
237

 
238

 
(0.5
)
     International
 
89

 
99

 
(10.5
)
 
292

 
321

 
(9.1
)
     Worldwide
 
167

 
175

 
(3.8
)
 
528

 
559

 
(5.4
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
68

 
50

 
35.3

 
196

 
179

 
9.7

     International
 
316

 
359

 
(12.5
)
 
1,035

 
1,161

 
(10.9
)
     Worldwide
 
384

 
409

 
(6.6
)
 
1,231

 
1,340

 
(8.2
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,171

 
1,250

 
(6.3
)
 
3,146

 
3,268

 
(3.7
)
     International
 
1,590

 
1,338

 
18.8

 
4,830

 
4,087

 
18.2

     Worldwide
 
2,761

 
2,588

 
6.7

 
7,976

 
7,355

 
8.4

     DARZALEX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
402

 
318

 
26.1

 
1,123

 
880

 
27.6

     International
 
363

 
180

 
*
 
1,045

 
561

 
86.2

     Worldwide
 
765

 
498

 
53.5

 
2,168

 
1,441

 
50.4

     IMBRUVICA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
447

 
334

 
34.0

 
1,163

 
811

 
43.5

     International
 
475

 
371

 
27.6

 
1,373

 
1,101

 
24.6

     Worldwide
 
921

 
705

 
30.6

 
2,536

 
1,912

 
32.6

     VELCADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—
 
—

 
—

 
—
     International
 
149

 
271

 
(44.8
)
 
636

 
864

 
(26.3
)
     Worldwide
 
149

 
271

 
(44.8
)
 
636

 
864

 
(26.3
)
     ZYTIGA® / abiraterone acetate
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
233

 
527

 
(55.8
)
 
616

 
1,420

 
(56.6
)
     International
 
508

 
431

 
17.8

 
1,502

 
1,292

 
16.2

     Worldwide
 
741

 
958

 
(22.7
)
 
2,118

 
2,712

 
(21.9
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
91

 
71

 
26.7
 
245

 
157

 
54.7

     International
 
95

 
85

 
12.2

 
274

 
269

 
2.1

     Worldwide
 
186

 
156

 
18.8

 
519

 
426

 
21.6

 
 
 
 
 
 
 
 
 
 
 
 
 

Pulmonary Hypertension
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
427

 
425

 
0.5
 
1,296

 
1,215

 
6.6

     International
 
227

 
231

 
(1.6)
 
704

 
691

 
1.9

     Worldwide
 
654

 
656

 
(0.3)
 
2,000

 
1,906

 
4.9

     OPSUMIT®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
206

 
182

 
12.9
 
581

 
511

 
13.7

     International
 
140

 
128

 
10.1
 
419

 
381

 
10.2

     Worldwide
 
347

 
310

 
11.7
 
1,001

 
892

 
12.2

     TRACLEER® / bosentan
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
19

 
69

 
(72.4)
 
121

 
208

 
(41.8
)
     International
 
46

 
70

 
(32.8)
 
164

 
214

 
(23.3
)
     Worldwide
 
65

 
139

 
(52.7)
 
285

 
422

 
(32.4
)
     UPTRAVI®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
185

 
154

 
20.2
 
536

 
433

 
23.9

     International
 
25

 
17

 
52.1
 
75

 
49

 
52.8

     Worldwide
 
210

 
171

 
23.4
 
611

 
482

 
26.8

     OTHER 
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
17

 
20

 
(10.1)
 
58

 
63

 
(8.9
)
     International
 
15

 
16

 
(15.4)
 
46

 
47

 
(3.0
)
     Worldwide
 
31

 
36

 
(12.6)
 
103

 
110

 
(6.4
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiovascular / Metabolism / Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
955

 
1,026

 
(6.9
)
 
2,804

 
3,230

 
(13.2
)
     International
 
360

 
365

 
(1.3
)
 
1,131

 
1,196

 
(5.4
)
     Worldwide
 
1,316

 
1,391

 
(5.4
)
 
3,936

 
4,426

 
(11.1
)
     XARELTO®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
613

 
612

 
0.1

 
1,704

 
1,869

 
(8.9
)
     International
 
—

 
—

 
—
 
—

 
—

 
—
     Worldwide
 
613

 
612

 
0.1

 
1,704

 
1,869

 
(8.9
)
     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
125

 
150

 
(16.6
)
 
411

 
523

 
(21.3
)
     International
 
55

 
40

 
33.9

 
147

 
130

 
12.3

     Worldwide
 
179

 
190

 
(5.8
)
 
558

 
653

 
(14.6
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
126

 
178

 
(29.6
)
 
387

 
523

 
(26.1
)
     International
 
72

 
77

 
(5.7
)
 
220

 
244

 
(9.8
)
     Worldwide
 
198

 
255

 
(22.4
)
 
607

 
767

 
(20.9
)
     OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
91

 
86

 
8.1

 
302

 
315

 
(3.8
)
     International
 
234

 
248

 
(5.7
)
 
765

 
822

 
(6.9
)
     Worldwide
 
325

 
334

 
(2.2
)
 
1,067

 
1,137

 
(6.1
)
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
6,340

 
6,097

 
4.0

 
17,705

 
17,350

 
2.0

     International
 
4,537

 
4,249

 
6.8

 
13,945

 
13,194

 
5.7

     Worldwide
 
10,877

 
10,346

 
5.1

 
31,650

 
30,544

 
3.6

 
 
 
 
 
 
 
 
 
 
 
 
 

MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
125

 
*
 
—

 
371

 
*
     International
 
—

 
190

 
*
 
—

 
638

 
*
     Worldwide
 
—

 
315

 
*
 
—

 
1,009

 
*
Interventional Solutions
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
357

 
320

 
11.5

 
1,066

 
947

 
12.6

     International
 
382

 
333

 
15.3

 
1,156

 
1,013

 
14.2

     Worldwide
 
741

 
653

 
13.4

 
2,223

 
1,960

 
13.4

Orthopaedics
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,301

 
1,284

 
1.2

 
3,950

 
3,923

 
0.7

     International
 
837

 
827

 
1.2

 
2,616

 
2,700

 
(3.1
)
     Worldwide
 
2,138

 
2,111

 
1.2

 
6,566

 
6,623

 
(0.9
)
     HIPS
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
204

 
201

 
1.1

 
633

 
621

 
1.8

     International
 
133

 
129

 
2.7

 
428

 
432

 
(0.8
)
     Worldwide
 
336

 
330

 
1.7

 
1,061

 
1,053

 
0.7

     KNEES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
209

 
215

 
(2.7
)
 
650

 
672

 
(3.3
)
     International
 
136

 
126

 
7.9

 
435

 
438

 
(0.6
)
     Worldwide
 
344

 
341

 
1.2

 
1,085

 
1,110

 
(2.2
)
     TRAUMA
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
415

 
395

 
5.1

 
1,239

 
1,196

 
3.6

     International
 
262

 
259

 
1.0

 
795

 
829

 
(4.1
)
     Worldwide
 
677

 
654

 
3.5

 
2,034

 
2,025

 
0.4

     SPINE & OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
472

 
473

 
(0.2
)
 
1,427

 
1,434

 
(0.5
)
     International
 
306

 
313

 
(2.0
)
 
957

 
1,001

 
(4.4
)
     Worldwide
 
778

 
786

 
(0.9
)
 
2,384

 
2,435

 
(2.1
)
Surgery
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
940

 
1,016

 
(7.4
)
 
2,867

 
3,031

 
(5.4
)
     International
 
1,371

 
1,360

 
0.8

 
4,192

 
4,283

 
(2.1
)
     Worldwide
 
2,311

 
2,376

 
(2.7
)
 
7,059

 
7,314

 
(3.5
)
     ADVANCED
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
409

 
421

 
(2.8
)
 
1,209

 
1,216

 
(0.6
)
     International
 
602

 
555

 
8.3

 
1,811

 
1,731

 
4.6

     Worldwide
 
1,010

 
976

 
3.6

 
3,019

 
2,947

 
2.4

     GENERAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
443

 
423

 
4.7

 
1,311

 
1,282

 
2.3

     International
 
659

 
657

 
0.2

 
1,998

 
2,094

 
(4.6
)
     Worldwide
 
1,101

 
1,080

 
1.9

 
3,309

 
3,376

 
(2.0
)
     SPECIALTY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
88

 
172

 
(48.0
)
 
347

 
533

 
(34.9
)
     International
 
110

 
148

 
(25.0
)
 
383

 
458

 
(16.2
)
     Worldwide
 
200

 
320

 
(37.4
)
 
731

 
991

 
(26.2
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Vision
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
459

 
452

 
1.4

 
1,366

 
1,351

 
1.1

     International
 
734

 
680

 
8.0

 
2,117

 
2,069

 
2.3

     Worldwide
 
1,193

 
1,132

 
5.4

 
3,483

 
3,420

 
1.8

     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
339

 
319

 
6.2

 
993

 
948

 
4.7

     International
 
555

 
516

 
7.4

 
1,566

 
1,538

 
1.8

     Worldwide
 
893

 
835

 
7.0

 
2,559

 
2,486

 
2.9

     SURGICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
120

 
133

 
(10.0
)
 
373

 
403

 
(7.4
)
     International
 
180

 
164

 
9.9

 
551

 
531

 
3.7

     Worldwide
 
299

 
297

 
0.9

 
923

 
934

 
(1.1
)
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,057

 
3,197

 
(4.4
)
 
9,249

 
9,623

 
(3.9
)
     International
 
3,326

 
3,390

 
(1.9
)
 
10,082

 
10,703

 
(5.8
)
     Worldwide
 
6,383

 
6,587

 
(3.1
)
 
19,331

 
20,326

 
(4.9
)
 
 
 
 
 
 
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
10,791

 
10,664

 
1.2

 
31,323

 
31,255

 
0.2

     International
 
9,938

 
9,684

 
2.6

 
29,989

 
29,932

 
0.2

     Worldwide
 
$
20,729

 
20,348

 
1.9
 %
 
$
61,312

 
61,187

 
0.2
 %

*Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business
EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 
 
Fiscal Third Quarter Ended
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 29,
2019
 
September 30,
2018
 
Percent
Change
 
September 29,
2019
 
September 30,
2018
 
Percent Change
Consumer (1)
 
$
653

 
510

 
28.0
 %
 
$
1,800

 
1,887

 
(4.6
)%
Pharmaceutical(2)
 
(222
)
 
2,876

 
*
 
5,786

 
10,193

 
(43.2
)
Medical Devices(3)
 
1,392

 
1,267

 
9.9

 
6,078

 
3,642

 
66.9

Segment earnings before provision for taxes
 
1,823

 
4,653

 
(60.8
)
 
13,664

 
15,722

 
(13.1
)
Less: Expense not allocated to segments (4)
 
176

 
230

 
 

 
554

 
845

 
 

Worldwide income before tax
 
$
1,647

 
4,423

 
(62.8
)%
 
$
13,110

 
14,877

 
(11.9
)%

*Percentage greater than 100% or not meaningful

(1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) in the fiscal nine months of 2019. Includes litigation expense of $0.2 billion and restructuring charge of $0.1 billion in the fiscal nine months of 2019. Includes a gain of $0.3 billion from the divestiture of NIZORAL® in the fiscal nine months of 2018. Includes amortization expense of $0.1 billion in both the fiscal third quarter of 2019 and 2018 and $0.3 billion and $0.2 billion in the fiscal nine months of 2019 and 2018, respectively.
 
(2) Includes litigation expense of $4.0 billion and $4.3 billion primarily related to the agreement in principle to settle opioid litigation in the fiscal third quarter and fiscal nine months of 2019, respectively. Includes an unrealized loss on securities of $0.1 billion in the fiscal third quarter of 2019. Includes an unrealized gain on securities of $0.2 billion, an in-process research and development expense of $0.9 billion related to the Alios asset, a research and development expense of $0.3 billion for an upfront payment related to argenx, Actelion acquisition related costs of $0.1 billion and restructuring charge of $0.1 billion in the fiscal nine months of 2019. Includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion in the fiscal third quarter and fiscal nine months of 2018. Includes Actelion acquisition related costs of $0.2 billion in the fiscal nine months of 2018 and a gain of $0.1 billion from the divestiture of PANCREASE® in the fiscal nine months of 2018. Includes amortization expense of $0.8 billion and $0.7 billion in the fiscal third quarters and $2.4 billion and $2.3 billion in the fiscal nine months of 2019 and 2018, respectively.
(3) Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal nine months of 2019. Includes a restructuring related charge of $0.1 billion and $0.2 billion in the fiscal third quarters of 2019 and 2018, respectively and $0.2 billion and $0.4 billion in the fiscal nine months of 2019 and 2018, respectively. Includes litigation expense of $0.3 billion and $0.7 billion in the fiscal nine months of 2019 and 2018, respectively. Includes amortization expense of $0.2 billion and $0.3 billion in the fiscal third quarters of 2019 and 2018, respectively and $0.7 billion and $0.8 billion in the fiscal nine months of 2019 and 2018, respectively.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
SALES BY GEOGRAPHIC AREA
 
 
Fiscal Third Quarter Ended
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 29, 2019
 
September 30, 2018
 
Percent
Change
 
September 29, 2019
 
September 30, 2018
 
Percent Change
United States
 
$
10,791

 
10,664

 
1.2
 %
 
$
31,323

 
31,255

 
0.2
 %
Europe
 
4,461

 
4,416

 
1.0

 
13,803

 
14,023

 
(1.6
)
Western Hemisphere, excluding U.S.
 
1,488

 
1,550

 
(4.0
)
 
4,446

 
4,657

 
(4.5
)
Asia-Pacific, Africa
 
3,989

 
3,718

 
7.3

 
11,740

 
11,252

 
4.3

Total
 
$
20,729

 
20,348

 
1.9
 %
 
$
61,312

 
61,187

 
0.2
 %